BETA ZEN
Biapenem
Texto da Wikipédia (en), licença CC BY-SA. O BETARUBI mostra o verbete inteiro nesta página — a leitura não continua fora do site.
 | |
| Clinical data | |
|---|---|
| Trade names | Omegacin, Bianem |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H18N4O4S |
| Molar mass | 350.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Biapenem (INN) is a carbapenem antibiotic sold in Japan under the brand name Omegacin,[1] and in India as Bianem.[2][3] It is a synthetic β-lactam antibiotic belonging to the carbapenems chemical class, developed by the Japanese subsidiary of Lederle Pharmaceuticals in the late 1980's.[4]
Biapenem was approved for use in Japan in 2001, and launched to market there in 2002,[5] with clinical trials approved in India in 2021,[2] and full market launch later the same year.[3] In clinical trials, it was found to be more effective at lower doses than imipenem, but less effective than equivalent doses of ceftazidime.[4]
Medical uses
Biapenem is effective against a wide range of gram-positive and gram-negative bacteria,[6][7] including Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Proteus mirabilis, Proteus vulgaris, and Morganella morganii.[4]
Unlike some other carbapenems, notably imipenem, biapenem is not particularly susceptible to hydrolysis by human renal dihydropeptidase-I (DHP-I), meaning it can be administered effectively without an adjunct like cilastatin.[8]
Resistance to biapenem is similar to that of imipenem, with similar mechanisms responsible.[9] It is most frequently given as an intravenous infusion.[10]
References
- ↑ Aldridge KE, Morice N, Schiro DD (April 1994). "In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes". Antimicrobial Agents and Chemotherapy. 38 (4): 889–893. doi:10.1128/aac.38.4.889. PMC 284564. PMID 8031067.
- 1 2 "Permission to conduct Clinical Trial for Biapenem Injection 300 mg (Form CT-06, File No. ND/MA/21/000018)" (PDF). Central Drugs Standard Control Organization (CDSCO), Government of India. 2021-04-22. Retrieved 2026-08-04.
- 1 2 Sharma, Ruchika (2021-09-25). "BDR Pharma gets DCGI nod for generic antibiotic drug Biapenem". Medical Dialogues. Retrieved 2026-08-04.
- 1 2 3 Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, et al. (June 1990). "In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I". Antimicrobial Agents and Chemotherapy. 34 (6): 994–1000. doi:10.1128/aac.34.6.994. PMC 171745. PMID 2203313.
- ↑ Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV (June 2013). "In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria". Antimicrobial Agents and Chemotherapy. 57 (6): 2620–2630. doi:10.1128/AAC.02418-12. PMC 3716157. PMID 23529731.
- ↑ Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, et al. (June 1998). "Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects". Antimicrobial Agents and Chemotherapy. 42 (6): 1433–1436. doi:10.1128/aac.42.6.1433. PMC 105618. PMID 9624490.
- ↑ Sloan RW (June 1992). "Principles of drug therapy in geriatric patients". American Family Physician. 45 (6): 2709–2718. PMID 1595518.
- ↑ Perry CM, Ibbotson T (2002). "Biapenem". Drugs. 62 (15): 2221–34, discussion 2235. doi:10.2165/00003495-200262150-00005. PMID 12381221.
- ↑ Chen HY, Livermore DM (May 1994). "In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms". The Journal of Antimicrobial Chemotherapy. 33 (5): 949–958. doi:10.1093/jac/33.5.949. PMID 8089068.
- ↑ Hara K, Baba S, Matsumoto F, Ooishi M, Kawada Y, Arata J, et al. (November 1999). "[Clinical evaluation of biapenem in various infectious diseases]" Clinical evaluation of biapenem in various infectious diseases. The Japanese Journal of Antibiotics (in Japanese). 52 (11): 629–660. PMID 10659441.
External links
- (in Japanese) Omegacin